Reactivation capacity by latency-reversing agents ex vivo correlates with the size of the HIV-1 reservoir.
Fiche publication
Date publication
janvier 2017
Journal
AIDS (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROHR Olivier
Tous les auteurs :
Darcis G, Bouchat S, Kula A, Van Driessche B, Delacourt N, Vanhulle C, Avettand-Fenoel V, De Wit S, Rohr O, Rouzioux C, Van Lint C
Lien Pubmed
Résumé
HIV-1 reservoirs are the major hurdle to virus clearance in combination antiretroviral therapy (cART)-treated patients. An approach to eradicating HIV-1 involves reversing latency in cART-treated patients to make latent cells visible to the host immune system. Stimulation of patient cell cultures with latency-reversing agents (LRAs) ex vivo results in heterogeneous responses among HIV-infected patients. Determinants of this heterogeneity are unknown and consequently important to determine.
Mots clés
Adult, Female, HIV Infections, virology, HIV-1, growth & development, Humans, Leukocytes, Mononuclear, drug effects, Male, Middle Aged, Virus Activation, Virus Latency, drug effects
Référence
AIDS. 2017 01 14;31(2):181-189